Research Trials

If you have any questions or are interested in participating in one of our clinical trials, please jot down the trial number and contact your Nebraska Cancer Specialists medical oncologist or a member of our clinical research team at 402.334.4773, or email us at clinicaltrials@nebraskacancer.com.

Download a PDF of All Current Trials
  • Cancer Type:

  • 20298

    A Phase II Study of VS-6766 Alone and in Combination with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

    Cancer Type: OVARIAN

    View Details on ClinicalTrials.gov
  • 18014

    A Phase I , Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and PK study of CX-4945 administered twice daily to patients with advanced basal cell carcinoma

    Cancer Type: BASAL CELL

    View Details on ClinicalTrials.gov
  • BNT111-01-4781

    Open-Label, randomized Phase II trial with BNT 111 and Cemiplimab in combination or as single agents in patients with anti-PD-1 refractory or relapsed, unresectable Stage III or IV melanoma

    Cancer Type: MELANOMA

    View Details on ClinicalTrials.gov
  • CA027002

    A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers

    Cancer Type: MELANOMA

    View Details on ClinicalTrials.gov
  • UV1-202

    A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma (UV1-202)

    Cancer Type: MELANOMA

    View Details on ClinicalTrials.gov
  • PIVOT-12

    A Phase III, Randomized, Open-Label study of Adjuvant Immunotherapy with Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Participants at High Risk for Recurrence (PIVOT-12)

    Cancer Type: MELANOMA

    View Details on ClinicalTrials.gov
  • RMC-4630-03

    A Phase II, Open-Label , Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C mutation after failure of prior standard therapies

    Cancer Type: LUNG

    View Details on ClinicalTrials.gov
  • RRx-001-33

    A Phase III, Controlled, Open Label, Randomized Study of RRx-001 administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

    Cancer Type: LUNG

    View Details on ClinicalTrials.gov
  • 20269

    A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-012)

    Cancer Type: LUNG

    View Details on ClinicalTrials.gov
  • 18129

    Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

    Cancer Type: LUNG

    View Details on ClinicalTrials.gov